← All trials
NCT05575518
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Oct 12, 2022
- Last posted
- Oct 12, 2022
- Enrollment
- 414
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kibong'oto Infectious Diseases HospitalLead sponsor
- Kibong'oto Infectious Diseases HospitalSponsor investigator
- Radboud UniversityCollaborator
- University of St AndrewsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.